This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (funded, already peer-reviewed, non-eHealth) (172) Malaria Surveillance and Prevention (26)

Published on in Vol 5, No 4 (2016): Oct-Dec

Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya

Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya

Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya

Authors of this article:

Menno R Smit1 Author Orcid Image ;   Eric Ochomo2 Author Orcid Image ;   Ghaith Aljayyoussi1 Author Orcid Image ;   Titus Kwambai2, 3 Author Orcid Image ;   Bernard Abong'o2 Author Orcid Image ;   Nabie Bayoh4 Author Orcid Image ;   John Gimnig4 Author Orcid Image ;   Aaron Samuels4 Author Orcid Image ;   Meghna Desai4 Author Orcid Image ;   Penelope A Phillips-Howard1 Author Orcid Image ;   Simon Kariuki2 Author Orcid Image ;   Duolao Wang1 Author Orcid Image ;   Steve Ward1 Author Orcid Image ;   Feiko O ter Kuile1 Author Orcid Image
Article Authors Cited by (23) Tweetations (109) Metrics

Journals

  1. El-Saber Batiha G, Alqahtani A, Ilesanmi O, Saati A, El-Mleeh A, Hetta H, Magdy Beshbishy A. Avermectin Derivatives, Pharmacokinetics, Therapeutic and Toxic Dosages, Mechanism of Action, and Their Biological Effects. Pharmaceuticals 2020;13(8):196 View
  2. Dabira E, Soumare H, Lindsay S, Conteh B, Ceesay F, Bradley J, Kositz C, Broekhuizen H, Kandeh B, Fehr A, Nieto-Sanchez C, Ribera J, Peeters Grietens K, Smit M, Drakeley C, Bousema T, Achan J, D’Alessandro U. Mass Drug Administration With High-Dose Ivermectin and Dihydroartemisinin-Piperaquine for Malaria Elimination in an Area of Low Transmission With High Coverage of Malaria Control Interventions: Protocol for the MASSIV Cluster Randomized Clinical Trial. JMIR Research Protocols 2020;9(11):e20904 View
  3. Smit M, Ochomo E, Aljayyoussi G, Kwambai T, Abong'o B, Chen T, Bousema T, Slater H, Waterhouse D, Bayoh N, Gimnig J, Samuels A, Desai M, Phillips-Howard P, Kariuki S, Wang D, Ward S, ter Kuile F. Safety and mosquitocidal efficacy of high-dose ivermectin when co-administered with dihydroartemisinin-piperaquine in Kenyan adults with uncomplicated malaria (IVERMAL): a randomised, double-blind, placebo-controlled trial. The Lancet Infectious Diseases 2018;18(6):615 View
  4. Chaccour C, Hammann F, Rabinovich N. Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety. Malaria Journal 2017;16(1) View
  5. Chaccour C, Hammann F, Alustiza M, Castejon S, Tarimo B, Abizanda G, Irigoyen Barrio Á, Martí Soler H, Moncada R, Bilbao J, Aldaz A, Maia M, Del Pozo J. Cytochrome P450/ABC transporter inhibition simultaneously enhances ivermectin pharmacokinetics in the mammal host and pharmacodynamics in Anopheles gambiae. Scientific Reports 2017;7(1) View
  6. Kobylinski K, Ubalee R, Ponlawat A, Nitatsukprasert C, Phasomkulsolsil S, Wattanakul T, Tarning J, Na-Bangchang K, McCardle P, Davidson S, Richardson J. Ivermectin susceptibility and sporontocidal effect in Greater Mekong Subregion Anopheles. Malaria Journal 2017;16(1) View
  7. Kobylinski K, Escobedo-Vargas K, López-Sifuentes V, Durand S, Smith E, Baldeviano G, Gerbasi R, Ballard S, Stoops C, Vásquez G. Ivermectin susceptibility, sporontocidal effect, and inhibition of time to re-feed in the Amazonian malaria vector Anopheles darlingi. Malaria Journal 2017;16(1) View
  8. al Jalali V, Zeitlinger M. Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents. Clinical Pharmacokinetics 2020;59(7):827 View
  9. Smit M, Ochomo E, Waterhouse D, Kwambai T, Abong'o B, Bousema T, Bayoh N, Gimnig J, Samuels A, Desai M, Phillips‐Howard P, Kariuki S, Wang D, ter Kuile F, Ward S, Aljayyoussi G. Pharmacokinetics‐Pharmacodynamics of High‐Dose Ivermectin with Dihydroartemisinin‐Piperaquine on Mosquitocidal Activity and QT‐Prolongation (IVERMAL). Clinical Pharmacology & Therapeutics 2019;105(2):388 View
  10. Smit M, Ochomo E, Aljayyoussi G, Kwambai T, Abong’o B, Bousema T, Waterhouse D, Bayoh N, Gimnig J, Samuels A, Desai M, Phillips-Howard P, Kariuki S, Wang D, Ward S, ter Kuile F. Human Direct Skin Feeding Versus Membrane Feeding to Assess the Mosquitocidal Efficacy of High-Dose Ivermectin (IVERMAL Trial). Clinical Infectious Diseases 2019;69(7):1112 View
  11. Muñoz J, Ballester M, Antonijoan R, Gich I, Rodríguez M, Colli E, Gold S, Krolewiecki A, Prichard R. Safety and pharmacokinetic profile of fixed-dose ivermectin with an innovative 18mg tablet in healthy adult volunteers. PLOS Neglected Tropical Diseases 2018;12(1):e0006020 View
  12. Scheim D. From Cold to Killer: How SARS-CoV-2 Evolved without Hemagglutinin Esterase to Agglutinate, Then Clot Blood Cells in Pulmonary and Systemic Microvasculature. SSRN Electronic Journal 2020 View
  13. Pessanha de Carvalho L, Kreidenweiss A, Held J. Drug Repurposing: A Review of Old and New Antibiotics for the Treatment of Malaria: Identifying Antibiotics with a Fast Onset of Antiplasmodial Action. Molecules 2021;26(8):2304 View
  14. Kositz C, Bradley J, Hutchins H, Last A, D'Alessandro U, Marks M. Broadening the range of use cases for ivermectin – a review of the evidence. Transactions of The Royal Society of Tropical Medicine and Hygiene 2022;116(3):201 View
  15. Singh A, Sheth P, Dhaneria S, Gupta D. Efficacy and safety of ivermectin for COVID-19. Asian Pacific Journal of Tropical Medicine 2021;14(10):440 View
  16. Mathachan S, Sardana K, Khurana A. Current Use of Ivermectin in Dermatology, Tropical Medicine, and COVID-19. Indian Dermatology Online Journal 2021;12(4):500 View
  17. Ekoka Mbassi D, Mombo-Ngoma G, Held J, Okwu D, Ndzebe-Ndoumba W, Kalkman L, Ekoka Mbassi F, Pessanha de Carvalho L, Inoue J, Akinosho M, Dimessa Mbadinga L, Yovo E, Mordmüller B, Kremsner P, Adegnika A, Ramharter M, Zoleko-Manego R. Efficacy and safety of ivermectin for the treatment of Plasmodium falciparum infections in asymptomatic male and female Gabonese adults – a pilot randomized, double-blind, placebo-controlled single-centre phase Ib/IIa clinical trial. eBioMedicine 2023;97:104814 View
  18. Ominde K, Kamau Y, Karisa J, Muturi M, Kiuru C, Wanjiku C, Babu L, Yaah F, Tuwei M, Musani H, Ondieki Z, Muriu S, Mwangangi J, Chaccour C, Maia M. A field bioassay for assessing ivermectin bio-efficacy in wild malaria vectors. Malaria Journal 2023;22(1) View
  19. Hutchins H, Bradley J, Pretorius E, Teixeira da Silva E, Vasileva H, Jones R, Ndiath M, dit Massire Soumare H, Mabey D, Nante E, Martins C, Logan J, Slater H, Drakeley C, D'Alessandro U, Rodrigues A, Last A. Protocol for a cluster randomised placebo-controlled trial of adjunctive ivermectin mass drug administration for malaria control on the Bijagós Archipelago of Guinea-Bissau: the MATAMAL trial. BMJ Open 2023;13(7):e072347 View
  20. Bello S, Imam M, Bello M, Yunusa A, Ahmed Adamu A, Shuaibu A, Igumbor E, Habib Z, Popoola M, Ochu C, Yahaya Bello A, Deeni Y, Okoye I. Erythromycin, retapamulin, pyridoxine, folic acid, and ivermectin inhibit cytopathic effect, papain-like protease, and MPRO enzymes of SARS-CoV-2. Frontiers in Cellular and Infection Microbiology 2023;13 View
  21. Bartilol B, Babu L, Garama K, Karisa J, Kamau A, Mwandawiro C, Wanjiku C, Mbogo C, Maia M, Mwangangi J, Rono M. Molecular xenomonitoring reveals Anopheles funestus and An. rivulorum as the primary vectors of lymphatic filariasis in coastal Kenya. Parasites & Vectors 2024;17(1) View

Books/Policy Documents

  1. D’Alessandro U. Towards Malaria Elimination - A Leap Forward. View